Abstract
Selective serotonin reuptake inhibitors (SSRI) are generally considered the drug class of first resort for persons with intellectual disability (ID) and mood disorders. This trend is consistent with the general population. While efficacy has been established, little has been done to look at side effect risk factors of SSRIs for persons with ID. In this study we describe data from the Matson Evaluation of Drug Side-Effects (MEDS) for 49 adults with mild to profound ID who were prescribed SSRIs (n = 13), SSRIs plus other psychotropic drugs (n = 15), or no psychotropics (n = 21). From these data we conclude that higher doses of SSRIs and prescription of additional psychotropic medications increase the possibility that undesirable side effects would emerge compared to controls.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Developmental and Physical Disabilities
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
